CAS |
No.74226-22-5 |
中文名称 |
盐酸达唑苄 |
英文名称 |
Dazoxiben Hydrochloride |
别名 |
UK-37248;达唑氧苯 |
分子式 |
C12H13ClN2O3 |
分子量 |
268.7 |
溶解性 |
Soluble in DMSO ≥5mg/mL |
纯度 |
≥98% |
外观(性状) |
White to off-white Solid |
储存条件 |
Powder:2-8℃,2 years;Insolvent(母液):-20℃,6 months;-80℃,1 year |
运输条件 |
冷藏运输 |
MDL |
MFCD00475663 |
SMILES |
C1=CC(=CC=C1C(=O)O)OCCN2C=CN=C2.Cl |
InChIKey |
PVKDFUXBDJPRGU-UHFFFAOYSA-N |
InChI |
InChI=1S/C12H12N2O3.ClH/c15-12(16)10-1-3-11(4-2-10)17-8-7-14-6-5-13-9-14;/h1-6,9H,7-8H2,(H,15,16);1H |
PubChem CID |
53000 |
靶点 |
thromboxane (TX) synthase |
通路 |
Metabolic Enzyme&Protease |
背景说明 |
Dazoxiben Hydrochloride是一种有效的血栓烷合酶 (thromboxane (TX) synthase) 抑制剂。 |
生物活性 |
Dazoxiben is a potent and orally active thromboxane (TX) synthase inhibitor[1]. |
IC50 |
Thromboxane (TX) synthase[1] |
In Vitro |
Dazoxiben inhibits TXB2 production in clotting human whole blood with an IC50 of 0.3 μM and causes parallel enhancement of PGE2 greater than PGF2 alpha greater than 6-keto-PGF1 alpha production[1].Dazoxiben inhibits TXB2 production in rat kidney glomeruli with an IC50 of 1.60 μM) than in rat whole blood (IC50= 0.32μM), and is not associated with changes in PGE2, PGF2 alpha and 6-keto-PGF1 alpha production[1]. |
In Vivo |
Dazoxiben (intraperitoneal administration; 100 μg/kg) produces a marked prolongation of the tail bleeding time with 96.8 ± 10.8 secs[2]. |
数据来源文献 |
[1]. Patrignani P, et al. Differential effects of dazoxiben, a selective thromboxane-synthase inhibitor, on platelet and renal prostaglandin-endoperoxide metabolism.J Pharmacol Exp Ther. 1984 Feb;228(2):472-7. [2]. Yu SM, et al. Pharmacological characterization of cinnamophilin, a novel dual inhibitor of thromboxane synthase and thromboxane A2 receptor.Br J Pharmacol. 1994 Mar;111(3):906-12. |
规格 |
1mg 5mg 10mg 25mg |
单位 |
瓶 |